244 related articles for article (PubMed ID: 31163235)
1. Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review.
Choi FD; Kraus CN; Elsensohn AN; Carley SK; Lehmer LM; Nguyen RT; Linden KG; Shiu J
J Am Acad Dermatol; 2020 Feb; 82(2):440-459. PubMed ID: 31163235
[TBL] [Abstract][Full Text] [Related]
2. Histopathologic PD-L1 Tumor Expression and Prognostic Significance in Nonmelanoma Skin Cancers: A Systematic Review.
Lehmer L; Choi F; Kraus C; Shiu J; de Feraudy S; Elsensohn A
Am J Dermatopathol; 2021 May; 43(5):321-330. PubMed ID: 33910221
[TBL] [Abstract][Full Text] [Related]
3. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
[TBL] [Abstract][Full Text] [Related]
4. Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers.
Komatsubara KM; Jeter J; Carvajal RD; Margolin K; Schadendorf D; Hauschild A
Am Soc Clin Oncol Educ Book; 2017; 37():641-650. PubMed ID: 28561682
[TBL] [Abstract][Full Text] [Related]
5. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
6. The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: A systematic review and meta-analysis.
Wang BC; Cao RB; Li PD; Fu C
Cancer Med; 2019 Oct; 8(13):5969-5978. PubMed ID: 31436392
[TBL] [Abstract][Full Text] [Related]
7. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
Pillai RN; Behera M; Owonikoko TK; Kamphorst AO; Pakkala S; Belani CP; Khuri FR; Ahmed R; Ramalingam SS
Cancer; 2018 Jan; 124(2):271-277. PubMed ID: 28960263
[TBL] [Abstract][Full Text] [Related]
9. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
[TBL] [Abstract][Full Text] [Related]
10. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
[TBL] [Abstract][Full Text] [Related]
11. Cardiac adverse events of PD-1 and PD-L1 inhibitors in cancer protocol for a systematic review and network meta-analysis: A protocol for systematic review.
Han D; Dong J; Li H; Ma T; Yu W; Song L
Medicine (Baltimore); 2020 Jan; 99(5):e18701. PubMed ID: 32000374
[TBL] [Abstract][Full Text] [Related]
12. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
[TBL] [Abstract][Full Text] [Related]
13. The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Lin LL; Lin GF; Luo Q; Chen XQ
Int Immunopharmacol; 2019 Dec; 77():105975. PubMed ID: 31704288
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Luo W; Wang Z; Tian P; Li W
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
[TBL] [Abstract][Full Text] [Related]
15. Review: PD-L1 as an emerging target in the treatment and prevention of keratinocytic skin cancer.
Vaishampayan P; Curiel-Lewandrowski C; Dickinson SE
Mol Carcinog; 2023 Jan; 62(1):52-61. PubMed ID: 36121318
[TBL] [Abstract][Full Text] [Related]
16. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Wang Y; Zhou S; Yang F; Qi X; Wang X; Guan X; Shen C; Duma N; Vera Aguilera J; Chintakuntlawar A; Price KA; Molina JR; Pagliaro LC; Halfdanarson TR; Grothey A; Markovic SN; Nowakowski GS; Ansell SM; Wang ML
JAMA Oncol; 2019 Jul; 5(7):1008-1019. PubMed ID: 31021376
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
Samimi M
Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
[TBL] [Abstract][Full Text] [Related]
18. The incidence of pseudoprogressive disease associated with programmed cell death 1/programmed cell death ligand 1 inhibitors: A meta-analysis.
Zhang J; Tan K; Jiang X; Zheng S; Li J; Xue C; Zhang X; Cui H
Medicine (Baltimore); 2021 Jul; 100(28):e26649. PubMed ID: 34260566
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for Merkel Cell Carcinoma.
Nagase K; Narisawa Y
Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials.
Peng TR; Wu TW
Thorac Cancer; 2019 May; 10(5):1176-1181. PubMed ID: 30969033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
